p38 Inhibitors: beyond pyridinylimidazoles

Bibliography

• FOSTER ML, HALLEY F, SOUNESS JE: Potential of p38 inhibitors in the treatment of rheumatoid arthritis. Drug News Perspect.9.(2000) 13:488–497.
   PubMed Web of Science ®Google Scholar
• •Predinical data for RPR- 19200765A and review of the different structural classes of p38 inhibitor focusing on possible reasons10.for the delays in their clinical development.
   Google Scholar
• RUTGEERTS P, D'HAENS G, TARGAN S et al: Efficacy and safety of retreatment with anti-tumor necrosis factor antibody11.(infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761–769.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis:12.a randomized, controlled trial. Ann. Intern. Med. (1999) 130:478–486.
   Google Scholar
• ELLIOT MJ, MAINI RN, FELDMANN M et al.: Randomized••double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-a (cA2) versus placebo in rheumatoid13.arthritis. Lancet (1994) 344:1105–1110.
   Google Scholar
• VAN DE PUTTE LB, RAU R, BREEDVELD FC et al.: Efficacy of the fully human anti-TNF antibody D2E7 in rheumatoid arthritis. Arthritis Rheum. (1999) 42:S400.14.
   Google Scholar
• COHEN SB: WOOLLEY JM, CT-JAN WW: Interleukin 1 receptor antagonist Anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol (2003) 30:225–231.
   PubMed Web of Science ®Google Scholar
• LEONARDI CL, POWERS JL, MATHESON RE et al.: Etanercept as monotherapy in patients with psoriasis. N Engl. J. Med. (2003) 349:2014-2022. 9.
   Google Scholar
• GOTTLIEB AB, EVANS R, LI S et al.: Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol (2004) 51:534–542.
   PubMed Web of Science ®Google Scholar
• PAUL A. WILSON S, BELHAM CM et al.: Stress activated protein kinases: activation, regulation and function. Cell. Signal. (1997) 9:403-410. NEWTON R, HOLDEN N: Inhibitors of p38 mitogen activated protein kinase potential as anti-inflammatory agents in asthma? Biodrugs (2003) 17:113–129.
   Google Scholar
• HAN J, LEE JD, JIANG Y, LI Z, FENG L, ULEVITCH RJ: Characterization of the structure and function of a novel MAP kinase kinase (MKK6). j Biol. Chem. (1996) 271:2886–2891.
   PubMed Web of Science ®Google Scholar
• LEE JC, LAYDON JT, McDONNELL PC et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature (1994) 372:739-746. The discovery of the molecular target for the 4(5)-aryl-5(4)-pyridyl-imidazoles anti-inflammatory agents.
   Google Scholar
• VERTEX USA: Vertex has suspended development of VX 745, a p38 MAP kinase inhibitor, which was in Phase II trials in the: USA and Europe as potential treatment for rheumatoid arthritis. Vertex Inc, Press release (September 2001).
   Google Scholar
• SmithKline Beechman (now GlaxoSmithKline) has discontinued development of SB 242235, a cytokine suppressor (SmithKline Beechman, April 1999). This product was in Phase I clinical studies in the UK (SmithKline Beechman, March 1999) and was being investigated as a potential treatment for rheumatoid arthritis (SmithKline Beechman, April 1999) R&D Focus Report March 272001.
   Google Scholar
• BOEHM JC, ADAMS JL: New inhibitors of p38 kinase. Expert Opin. Ther. Patents (2000) 10:25–37.
   Web of Science ®Google Scholar
• ••Review of p38 inhibitors covering thepatent literature through 1999.
   Google Scholar
• JACKSON PF, BULLINGTON JL: Pyridinylimidazole based p38 MAP kinase inhibitors. Curr. Top. Med. Chem. (2002) 2:1011–1020.
   PubMedGoogle Scholar
• •A recent review
   Google Scholar
• ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimidazole inhibitors of CSBP/ p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes. Bioorg. Med. Chem. Lett. (1998) 8:3111–3118.
   PubMed Web of Science ®Google Scholar
• ADAMS JL, BOEHM JC, GALLAGHER TF et al: Pyrimidinyimidazole inhibitors of p38: cyclic N-imidazole substituents enhance p38 kinase inhibition and oral activity. Bioorg. Med. Chem. Lett. (2001) 11:2867–2870.
   PubMed Web of Science ®Google Scholar
• FULLERTON T, SHARMA A, PRABHAKAR U et al.: Suppression of ex vivo cytokine production by SB-242235, a selective inhibitor of p38 MAP kinase. Clin. Pharmacol Ther. (2000) 67:114.
   Google Scholar
• REVESZ L, BLUM E, DIPADOVA FE et al.: Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg. Med. Chem. Lett. (2004) 14:3595–3599.
   PubMedGoogle Scholar
• REVESZ L, DIPADOVA FE, BUHL T et al.: SAP. of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors. Bioorg. Med. Chem. Lett. (2000) 10:1261–1264.
   Google Scholar
• REVESZ L, DIPADOVA FE, BUHL T et al: SAP. of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38 MAP kinase inhibitors. Bioorg. Med. Chem. Lett. (2002) 12:2109–2112. 814
   Google Scholar
• DOMBROSKI MA, LETAVIC MA, MCCLURE KF et al.: Benzimidazolone p38 inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:919–923.
   Google Scholar
• MCINTYRE CJ, PONTICELLO GS, LIVERTON NJ et al.: Pyridazine based inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett. (2002) 12:689–692.
   PubMed Web of Science ®Google Scholar
• RUPERT KC, HENRY JR, DODD JH et al.: Imidazopyrimidines, potent inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. (2003) 13:347–350.
   PubMed Web of Science ®Google Scholar
• LAUFERSWEILER MJ, BRUGEL TA, CLARK MP et al.: The development of novel inhibitors of tumor necrosis factor-a (TNF-a) production based on substituted [5,5]-bicyclic pyrazolones. Bioorg. Med. Chem. Lett. (2004) 14:4267–4272.
   PubMed Web of Science ®Google Scholar
• TOWNES JA, GOLEBIOWSKI A, CLARK MP et al.: The development of new bicyclic pyrazole-based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4945–4948.
   Google Scholar
• GODL K, WISSING J, KURTENBACH A et al.: An efficient proteomics method to identify the cellular targets of protein kinase inhibitors. Proc. NatL Acad. Sci. USA (2003) 100:15434–15439.
   PubMed Web of Science ®Google Scholar
• OTTOSEN ER, SORENSEN MD, BJORKLING F et al.: Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity. J. Med. Chem. (2003) 46:5651–5662.
   Google Scholar
• LEO PHARMACEUTICALS: Press release (April 2002).
   Google Scholar
• REVESZ L, BLUM E, DIPADOVA FE et al.: SAP. of benzoylpyridines and benzophenones as p38 MAP kinase inhibitors with oral activity. Bioorg. Med. Chem. Lett. (2004) 14:3601–3605.
   Google Scholar
• VERTEX PHARMACEUTICALS, INC.: Press release (September 2001).
   Google Scholar
• VERTEX PHARMACEUTICALS, INC.: Press release (May 2003 and April 2004).
   Google Scholar
• LIU L, STELMACH JE, NATARAJAN SR et al.: SAP. of 3,4-dihydropyrido [3,2-pyrimidone p38 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:3979–3982.
   Google Scholar
• FITZGERALD CE, PATEL SB,BECKER JW et al.: Structural basis for p38a MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat. Struc. Biol. (2003) 10:764–769.
   Google Scholar
• MAVUNKEL BJ, CHAKRAVARTY S, PERUMATTAM JJ et al.: Indole-based heterocyclic inhibitors of p38a MAP kinase: designing a conformationally restricted analogue. Bioorg. Med. Chem. Lett. (2003) 13:3087–3090.
   PubMed Web of Science ®Google Scholar
• TONG SE, DANIELS SE, CHANG S et al.: SCIO 469, a novel p38a MAPK inhibitor, provides efficacy in acute post-surgical dental pain. Clin. Pharm. Ther. (2004) 75(2):3.
   Google Scholar
• MAVUNKEL B, CHAKRAVATY S, PERUMATTAM JJ et al.: Discovery & biological evaluation of p38a MAP kinase Inhibitor SX-011. International Symposium on Advances in Synthetic, CombinatoriaL and Medicinal Chemistry. Moscow, Russia (May 5–8 2004).
   Google Scholar
• Annual Press Conference 2003: Boehringer Ingelheim Company Presentation. (8 April 2003).
   Google Scholar
• REGAN J, BREITFELDER S, CIRILLO Pet al.: Pyrazole urea-base inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J. Med. Chem. (2002) 45:2994–3008.
   Google Scholar
• CUMMING JC, McKENZIE CL, BOWDEN SG et al.: Novel, potent and selective anilinoquinazoline and anilinopyrimidine inhibitors of p38 MAP kinase. Bioorg. Med. Chem. Lett. (2004) 14:5389–5394.
   Google Scholar